| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/155.1.93 |
| P698 | PubMed publication ID | 3540140 |
| P2093 | author name string | Smith CR | |
| Moore RD | |||
| Lietman PS | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 93-99 | |
| P577 | publication date | 1987-01-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | |
| P478 | volume | 155 |
| Q31075196 | A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced Data |
| Q38680501 | A Population Pharmacokinetic Model of Gentamicin in Pediatric Oncology Patients To Facilitate Personalized Dosing |
| Q54663296 | A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology. |
| Q42545727 | A comparison of two amikacin dosing regimens in paediatric surgical patients |
| Q52078881 | A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides. |
| Q40809870 | A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. |
| Q46391236 | A pilot study of netilmicin pharmacokinetics during continuous venovenous hemodiafiltration |
| Q84993227 | A priori prediction of gentamicin peak concentrations: Use of a simple and practical tool |
| Q43446209 | A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients |
| Q52081442 | A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. |
| Q40689023 | A study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis. |
| Q54296189 | Accumulation of amikacin in synovial fluid after regional limb perfusion of amikacin sulfate alone and in combination with ticarcillin/clavulanate in horses. |
| Q34589031 | Accuracy of empiric gentamicin dosing guidelines in neonates |
| Q33714230 | Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials |
| Q39881843 | Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. |
| Q35135145 | Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model |
| Q73235695 | Adjuvant treatment of deep sternal wound infection with collagenous gentamycin |
| Q36924742 | Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia |
| Q33938974 | Ambulatory use of parenteral antibacterials: contemporary perspectives |
| Q93085292 | Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients |
| Q48528055 | Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients |
| Q38850670 | Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies |
| Q34290150 | Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa |
| Q52424747 | Amikacin once daily: a new dosing regimen based on drug pharmacokinetics. |
| Q64129066 | Aminoglycoside Dosing in Obesity |
| Q43842726 | Aminoglycoside and vancomycin serum concentration monitoring and mortality due to neonatal sepsis in Saudi Arabia. |
| Q39634450 | Aminoglycoside antibiotics in clinical use. |
| Q40720366 | Aminoglycoside dosage regimens. Is once a day enough? |
| Q40794034 | Aminoglycoside dosing considerations in intensive care unit patients |
| Q35111974 | Aminoglycoside dosing weight correction factors for patients of various body sizes |
| Q54198578 | Aminoglycoside dosing: time to change. |
| Q72556345 | Aminoglycoside monitoring in the once- or twice-daily era. The Dutch situation considered |
| Q37941557 | Aminoglycoside therapy. Current use and future prospects |
| Q35645042 | Aminoglycoside therapy: current and prospective uses |
| Q40081223 | Aminoglycoside use in a pediatric hospital: there is room for improvement-a before/after study |
| Q38246945 | Aminoglycoside-induced nephrotoxicity |
| Q72336039 | Aminoglycosides |
| Q36887935 | Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae |
| Q43872720 | Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate? |
| Q38090988 | Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk |
| Q33548221 | Aminoglycosides: activity and resistance |
| Q39608639 | Aminoglycosides: current role in antimicrobial therapy |
| Q33605648 | Aminoglycosides: nephrotoxicity |
| Q54249096 | An evaluation of serum gentamicin concentrations and bacterial susceptibility to gentamicin in equine practice. |
| Q34470946 | An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. |
| Q40631933 | An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients. German Multicentre Study Group |
| Q37352354 | An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics |
| Q44917117 | Animal model methodology: immunocompetent or leucopenic rats, which is the best? Results from a model of experimental pneumonia due to derepressed cephalosporinase-producing Enterobacter cloacae |
| Q40913492 | Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem |
| Q36554698 | Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis |
| Q37215272 | Antibiotic Choices in Surgical Intensive Care Unit Patients |
| Q38261172 | Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much". |
| Q37852466 | Antibiotic dosing in critical illness |
| Q40526811 | Antibiotic kinetics and dynamics for the clinician. |
| Q35944927 | Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness |
| Q44405663 | Antibiotic prophylaxis with cefazolin and gentamicin in cardiac surgery for children less than ten kilograms |
| Q40432517 | Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA |
| Q93053117 | Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa |
| Q52685491 | Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy. |
| Q36863646 | Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response |
| Q41750885 | Antibiotic use in the critical care unit |
| Q36740036 | Antibiotics and antifungals in neonatal intensive care units: a review |
| Q33736248 | Antibiotics in neonatal infections: a review. |
| Q38748249 | Antibiotics in the treatment of wounds |
| Q57549163 | Antimicrobial Agents |
| Q30326190 | Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. |
| Q37733663 | Antimicrobial delivery by intrasynovial catheterisation with systemic administration for equine synovial trauma and sepsis |
| Q45982981 | Antimicrobial pharmacodynamics. |
| Q35095235 | Antimicrobial resistance in livestock |
| Q44752436 | Antimicrobial resistance of Neisseria gonorrhoeae in Liberia |
| Q41642553 | Antimicrobial therapy for respiratory disease |
| Q35630766 | Antimicrobial treatment guidelines for acute bacterial rhinosinusitis |
| Q77297373 | Antimicrobial treatment guidelines for acute bacterial rhinosinusitis |
| Q35348258 | Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve |
| Q40378234 | Application of guidelines for aminoglycosides use in French hospitals in 2013-2014. |
| Q36523688 | Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens |
| Q84629245 | Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock |
| Q41369580 | Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase. |
| Q37411815 | Assessment of gentamicin 7 mg/kg once daily for pediatric patients with febrile neutropenia: a pilot project |
| Q30838132 | Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up |
| Q58106372 | Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients? |
| Q37650115 | Augmented renal clearance: implications for antibacterial dosing in the critically ill. |
| Q43700878 | BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia |
| Q36916092 | Back to the future: using aminoglycosides again and how to dose them optimally |
| Q33980188 | Bactericidal activity of gentamicin against Enterococcus faecalis in vitro and in vivo. |
| Q50076206 | Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients |
| Q33770248 | Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation |
| Q40561487 | Bayesian pharmacokinetic analysis of a gentamicin nomogram in neonates: a retrospective study |
| Q24813204 | Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit |
| Q35109053 | Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis model |
| Q40459002 | Beta-Lactam Antibiotics: Is Continuous Infusion The Preferred Method of Administration? |
| Q94563599 | Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics |
| Q37838126 | Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter? |
| Q34320945 | Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes |
| Q35334285 | Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis |
| Q39557669 | Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure. |
| Q44028214 | Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation |
| Q33977551 | Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model |
| Q46145943 | Circadian variation in serum amikacin levels |
| Q45734205 | Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices |
| Q38138835 | Clinical implications of antibiotic pharmacokinetic principles in the critically ill. |
| Q35043373 | Clinical issues surrounding once-daily aminoglycoside dosing in children |
| Q34752069 | Clinical microdialysis in skin and soft tissues: an update |
| Q33882620 | Clinical pharmacokinetics and pharmacodynamics of isepamicin |
| Q40860727 | Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? |
| Q35981469 | Clinical pharmacokinetics of antibiotics in patients with impaired renal function |
| Q40884111 | Clinical pharmacokinetics of newer antibacterial agents in liver disease |
| Q37029217 | Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults |
| Q38625262 | Clinical significance of antibiotic tissue penetration |
| Q45894365 | Comment: Nephrotoxicity from once-daily dosing of gentamicin |
| Q74798763 | Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues |
| Q42549535 | Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa |
| Q46728031 | Comparative pharmacokinetics of amikacin in Greyhound and Beagle dogs. |
| Q39828366 | Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance |
| Q39097052 | Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis |
| Q28346609 | Comparison of 2 techniques for regional antibiotic delivery to the equine forelimb: intraosseous perfusion vs. intravenous perfusion |
| Q35885240 | Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children |
| Q35123139 | Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections |
| Q61811302 | Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureus |
| Q74183820 | Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants > or = 2500 g |
| Q43684609 | Comparison of two methods to obtain a desired first isepamicin peak in intensive care patients |
| Q40881689 | Comparison of two tourniquet application times for regional intravenous limb perfusions with amikacin in sedated or anesthetized horses |
| Q39558024 | Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model |
| Q24202497 | Computerized advice on drug dosage to improve prescribing practice |
| Q36329228 | Continuous beta-lactam infusion in critically ill patients: the clinical evidence |
| Q24199096 | Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections |
| Q36316972 | Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters |
| Q36240858 | Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials |
| Q43298353 | Controlled release antibiotics for dry powder lung delivery |
| Q36754206 | Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model |
| Q40730362 | Cost considerations in therapeutic drug monitoring of aminoglycosides |
| Q34730669 | Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance |
| Q40681427 | Critically-ill patients receiving total parenteral nutrition show altered amikacin pharmacokinetics |
| Q37839231 | Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity |
| Q35627814 | Delivering antibacterials to the lungs: considerations for optimizing outcomes. |
| Q42247460 | Determination of tobramycin pharmacokinetics in burn patients to evaluate the potential utility of once-daily dosing in this population |
| Q59621175 | Development of a Semimechanistic Model to Describe the Pharmacokinetics of Gentamicin in Patients Receiving Hemodialysis |
| Q45984535 | Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. |
| Q34106959 | Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection model |
| Q52595189 | Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model. |
| Q33937527 | Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics |
| Q38693212 | Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View |
| Q26853629 | Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics |
| Q33694513 | Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms |
| Q51930719 | Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. |
| Q34168527 | Drugs affecting the respiratory system. |
| Q46054047 | Effect of Dose on Intra-Articular Amikacin Sulfate Concentrations Following Intravenous Regional Limb Perfusion in Horses |
| Q48182661 | Effect of experimentally induced synovitis on amikacin concentrations after intravenous regional limb perfusion |
| Q48902837 | Effects of blood loss and fluid volume replacement on serum and tissue gentamicin concentrations during colorectal surgery. |
| Q34694922 | Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin |
| Q43275699 | Efficacy and safety of a single daily dose of gentamicin in hospitalized Indian children: a quasi-randomized trial |
| Q44041308 | Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients. |
| Q39865002 | Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis |
| Q44207951 | Efficacy of spectinomycin against Mycoplasma bovis induced pneumonia in conventionally reared calves |
| Q35259780 | Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis |
| Q44993453 | Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections. |
| Q36089167 | Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance |
| Q38880999 | Empirical gentamicin dosing based on serum creatinine levels in premature and term neonates |
| Q39852383 | Evaluation of 10-minute versus 30-minute tourniquet time for intravenous regional limb perfusion with amikacin sulfate in standing sedated horses |
| Q37653435 | Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen |
| Q38823748 | Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis |
| Q39221496 | Evaluation of four once-daily aminoglycoside dosing nomograms |
| Q44746169 | Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation |
| Q40036111 | Evaluation of regional limb perfusion with amikacin using the saphenous, cephalic, and palmar digital veins in standing horses |
| Q36191093 | Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis |
| Q35808500 | Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model |
| Q43280018 | Evaluation of various gentamicin dosage regimens in geriatric patients: a simulation study |
| Q35355587 | Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin |
| Q39779327 | Experience with a once-daily aminoglycoside program administered to 2,184 adult patients |
| Q33767602 | Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections |
| Q34615905 | Extended interval aminoglycoside dosing: from concept to clinic |
| Q35745888 | Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis |
| Q37237625 | Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries. |
| Q40751575 | Extended-interval gentamicin administration in neonates: a simplified approach |
| Q35566356 | Extended-interval gentamicin dosing in achieving therapeutic concentrations in malaysian neonates |
| Q35618184 | Extracorporeal removal of antimicrobials during plasmapheresis |
| Q51187710 | Fatality due to septicemia and hemorrhage in a patient with spinal cord injury and ischemic heart disease with the need for long-term catheter drainage. |
| Q33751758 | Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics |
| Q36752618 | First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. |
| Q43546296 | General principles of antibiotic therapy |
| Q35125906 | Gentamicin concentrations in human subcutaneous tissue |
| Q34291143 | Gentamicin dosing in critically ill patients |
| Q35562787 | Gentamicin dosing strategies for dogs with subclinical renal dysfunction |
| Q42952777 | Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered |
| Q36980151 | Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia |
| Q36754353 | Gentamicin pharmacokinetics in patients with malignancies |
| Q57238214 | Gentamicin volume of distribution in critically ill septic patients |
| Q40724877 | Gram-negative bacteremia |
| Q72065590 | Growth kinetics of L1210 leukemic cells exposed to different concentration courses of methotrexate in vitro |
| Q55091640 | Guidelines for the treatment of severe acute malnutrition: a systematic review of the evidence for antimicrobial therapy. |
| Q34923038 | Has antifungal susceptibility testing come of age? |
| Q38362712 | Hernia, mesh, and topical antibiotics, especially gentamycin: seeking the evidence for the perfect outcome…. |
| Q50319655 | High-dose amikacin for achieving serum target levels in critically ill elderly patients. |
| Q50356292 | High-dose gentamicin in newborn infants: is it safe? |
| Q34894900 | How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? |
| Q34615900 | How predictive is PK/PD for antibacterial agents? |
| Q35845654 | Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditis |
| Q40474926 | Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. |
| Q37389435 | Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. |
| Q35862757 | Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials |
| Q38035302 | Impact of dosage schedule of antibiotics on the treatment of serious infections |
| Q36752610 | Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation |
| Q41516734 | Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. |
| Q41810184 | Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats |
| Q94328620 | In situ gentamicin concentrations in cortical boneAn experimental study using microdialysis in bone |
| Q33694035 | In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. |
| Q35104038 | In vitro antibacterial activity and pharmacodynamics of new quinolones |
| Q43747971 | In vitro pharmacodynamic analysis of single daily dosing versus conventional dosing of gentamicin administered with penicillin against Enterococcus faecalis |
| Q54165365 | In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin. |
| Q33979115 | In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model |
| Q35114527 | In vivo verification of in vitro model of antibiotic treatment of device-related infection |
| Q35253342 | Increased aminoglycoside dosage requirements in hematologic malignancy |
| Q34397569 | Individualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations |
| Q34274190 | Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions |
| Q46078844 | Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. |
| Q53070940 | Individualising Therapy to Minimize Bacterial Multidrug Resistance. |
| Q37119964 | Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy |
| Q39818938 | Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits |
| Q36505518 | Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection |
| Q35925366 | Inhaled therapeutics for prevention and treatment of pneumonia |
| Q39557676 | Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047. |
| Q73410512 | Interpretive criteria for susceptibility testing of coagulase-negative staphylococci with special reference to netilmicin |
| Q89869284 | Intracerebroventricular drug administration |
| Q39679087 | Intraosseous gentamicin perfusion of the distal metacarpus in standing horses. |
| Q43453146 | Is double coverage of gram-negative organisms necessary? |
| Q35637864 | Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC |
| Q39616905 | Key pharmacokinetic parameters of isepamicin in febrile neutropenic cancer patients and in women with acute pelvic inflammatory disease |
| Q46521460 | Kinetic mechanism of streptomycin adenylyltransferase from a recombinant Escherichia coli |
| Q37392263 | Laboratory tests used to guide antimicrobial therapy |
| Q28194278 | Limited predictability of amikacin clearance in extreme premature neonates at birth |
| Q34336654 | Local application of gentamicin collagen implants in the prophylaxis of surgical site infections following gastrointestinal surgery: a review of clinical experience |
| Q42908869 | Management of Aminoglycosides in the Intensive Care Unit |
| Q41149840 | Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin |
| Q67946286 | More is better. Antibiotic management after hemorrhagic shock |
| Q35005097 | Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis |
| Q34028070 | New developments and concepts in antimicrobial therapy for intra-abdominal infections |
| Q34139570 | New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. |
| Q33885871 | New pharmacodynamic parameters for antimicrobial agents |
| Q47223964 | No role for patient body weight on renal function assessment for drug dosing |
| Q34106577 | Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children |
| Q35991121 | Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity? |
| Q46035187 | Once daily dose gentamicin in neonates - is our dosing correct? |
| Q72726142 | Once daily dosing of netilmicin in neonatal and pediatric intensive care |
| Q40627605 | Once-daily administration of aminoglycosides |
| Q35270646 | Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration |
| Q33569075 | Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects |
| Q38239743 | Once-daily aminoglycoside administration: new strategies for an old drug |
| Q35820928 | Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa |
| Q35738386 | Once-daily aminoglycoside dosing: An update on current literature |
| Q37730823 | Once-daily aminoglycoside therapy |
| Q34985783 | Once-daily aminoglycosides in patients with neutropenic fever |
| Q33659372 | Once-daily aminoglycosides in the treatment of gram-positive endocarditis |
| Q33928699 | Once-daily dosing of aminoglycoside antibiotics |
| Q46860894 | Once-daily dosing of aminoglycosides |
| Q35597011 | Once-daily gentamicin dosing for the preterm and term newborn: proposal for a simple regimen that achieves target levels |
| Q37661501 | Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy. |
| Q50324925 | Once-daily gentamicin dosing versus thrice-daily dosing in infants with acute pyelonephritis |
| Q40625355 | Once-daily versus multiple-daily gentamicin in empirical antibiotic therapy of febrile neutropenia following intensive chemotherapy |
| Q30901078 | Optimal aminoglycoside dosing regimen for penicillin-tobramycin synergism in experimental Streptococcus adjacens endocarditis |
| Q41963116 | Optimal aminoglycoside therapy following the sepsis: how much is too much? |
| Q33518061 | Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study |
| Q38133781 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. |
| Q38077518 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary |
| Q54250219 | Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling. |
| Q38672016 | Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance |
| Q33976467 | Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria |
| Q35914401 | Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem |
| Q93157454 | Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation - a retrospective study |
| Q36158283 | Optimizing the initial amikacin dosage in adults |
| Q37021224 | Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics |
| Q40913641 | Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: Medical, socioeconomic, and legal issues. Selecting the antibiotic |
| Q40392377 | Parenteral aminoglycoside therapy. Selection, administration and monitoring |
| Q36290620 | Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy |
| Q46373003 | Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia |
| Q38944862 | Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae |
| Q73167979 | Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside |
| Q28328534 | Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection |
| Q42543348 | Pharmacodynamics and alternative antimicrobial dosing regimens |
| Q35623060 | Pharmacodynamics and dosing of aminoglycosides |
| Q34069810 | Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time |
| Q35810298 | Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis |
| Q33981712 | Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model |
| Q34443415 | Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside |
| Q41014098 | Pharmacodynamics of antimicrobial therapy in surgery. |
| Q36544935 | Pharmacodynamics of antimicrobials: treatment optimisation |
| Q33981666 | Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection |
| Q33695281 | Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. |
| Q39650985 | Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model |
| Q40949900 | Pharmacoeconomic evaluation of once-daily aminoglycoside treatment |
| Q29248398 | Pharmacokinetic Changes and Dosing Modification of Aminoglycosides in Critically Ill Obese Patients: A Literature Review |
| Q36083619 | Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. |
| Q39866827 | Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin |
| Q35819409 | Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction |
| Q35688447 | Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases |
| Q87043419 | Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis |
| Q89144464 | Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient |
| Q44361848 | Pharmacokinetic dosing of aminoglycosides: a controlled trial |
| Q43869942 | Pharmacokinetic model for tobramycin in acinetobacter meningitis |
| Q37621548 | Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates |
| Q40326667 | Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants |
| Q35127921 | Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus |
| Q38626980 | Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization |
| Q33827819 | Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology |
| Q35985436 | Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine |
| Q39740646 | Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids |
| Q35066606 | Pharmacokinetics and antibacterial activity of daily gentamicin |
| Q57530101 | Pharmacokinetics and dosing regimen of aminosidine in the dog |
| Q34297656 | Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients |
| Q36911111 | Pharmacokinetics and pharmacodynamics of antibacterial agents |
| Q43738821 | Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients |
| Q77793516 | Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy |
| Q44104691 | Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing |
| Q34632230 | Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects |
| Q37046067 | Pharmacokinetics of a combination of amikacin sulfate and penicillin G sodium for intravenous regional limb perfusion in adult horses |
| Q51742431 | Pharmacokinetics of antibiotics in critically ill patients. |
| Q35136143 | Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. |
| Q46438079 | Pharmacokinetics of gentamicin in healthy adult horses during intravenous fluid administration |
| Q88674208 | Pharmacokinetics of intravenous gentamicin in healthy young-adult compared to aged alpacas |
| Q43672068 | Pharmacokinetics of once-a-day netilmicin (4.5 mg/kg) in neonates |
| Q42162184 | Pharmacokinetics of once-daily amikacin in healthy foals and therapeutic drug monitoring in hospitalized equine neonates |
| Q77695972 | Pharmacokinetics of once-daily amikacin in pediatric patients |
| Q73582979 | Pharmacokinetics of once-daily dosing of gentamicin in neonates |
| Q33789502 | Pharmacologic considerations in the treatment of neonatal septicemia and its complications |
| Q37956403 | Pharmacological considerations for the proper clinical use of aminoglycosides |
| Q40502026 | Pharmacological management of pain and infection in the surgical oncology patient |
| Q37557851 | Pharmacological rationale for antibiotic treatment of intra-abdominal infections |
| Q38696468 | Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates |
| Q37026635 | Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis |
| Q36975688 | Plasma Peak and Trough Gentamicin Concentrations in Hospitalized Horses Receiving Intravenously Administered Gentamicin |
| Q99580010 | Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance |
| Q37538698 | Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria |
| Q92657119 | Population Pharmacokinetics with Monte Carlo Simulations of Gentamicin in a Population of Severely Ill Adult Patients from Sub-Saharan Africa |
| Q39071799 | Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. |
| Q33692660 | Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults |
| Q39781863 | Population pharmacokinetic study of isepamicin with intensive care unit patients |
| Q35127932 | Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus |
| Q89635879 | Population pharmacokinetics of amikacin administered once-daily in patients with different renal function |
| Q35125654 | Population pharmacokinetics of amikacin in critically ill patients |
| Q35802610 | Population pharmacokinetics of gentamicin in patients with cancer |
| Q30498412 | Population pharmacokinetics of netilmicin in short-term prophylactic treatment |
| Q41696202 | Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. |
| Q46172261 | Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis |
| Q40949882 | Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy |
| Q39829144 | Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients |
| Q47176463 | Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen |
| Q58766376 | Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation |
| Q35598435 | Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration |
| Q68509565 | Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections |
| Q44996391 | Protective effect of aminoguanidine against nephrotoxicity induced by amikacin in rats. |
| Q48514081 | Quantitative analysis of gentamicin exposure in neonates and infants calls into question its current dosing recommendations. |
| Q34615878 | Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations |
| Q46376140 | Recommendations for antibiotic monitoring in ICU patients |
| Q39735382 | Relationship between pharmacodynamic indices and killing patterns in vitro. |
| Q30583748 | Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours |
| Q44136341 | Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections |
| Q72793341 | Review of beta-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules |
| Q33919190 | Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock |
| Q34347932 | Role of pharmacokinetics and pharmacodynamics: does the dose matter? |
| Q39639407 | Role of pharmacokinetics in the outcome of infections |
| Q34487181 | Role of topical application of gentamicin containing collagen implants in cardiac surgery |
| Q35185724 | Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations |
| Q40392363 | Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal |
| Q80547906 | Serum calcium values in term and late-preterm neonates receiving gentamicin |
| Q35913176 | Setting and revising antibacterial susceptibility breakpoints |
| Q40271712 | Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response? |
| Q37977592 | Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage |
| Q36496656 | Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics |
| Q36517464 | Single daily dose therapy with aminoglycosides |
| Q36755849 | Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding |
| Q41776282 | Source of phosphate in the enzymic reaction as a point of distinction among aminoglycoside 2''-phosphotransferases. |
| Q44275415 | Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. |
| Q36247318 | Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance |
| Q43716998 | Studies on drug monitoring in thrice and once daily treatment with aminoglycosides |
| Q67976475 | Successful treatment of empyema thoracis with polymethylmethacrylate antibiotic-impregnated beads in the guinea pig |
| Q46846782 | Synovial fluid and plasma concentrations of ceftiofur after regional intravenous perfusion in the horse |
| Q36536423 | Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study |
| Q33696025 | The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams |
| Q28289744 | The Pharmacokinetics and Pharmacodynamics of the Carbapenems: Focus on Doripenem |
| Q41138730 | The aminoglycosides |
| Q54399156 | The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, and sisomicin. |
| Q35875929 | The changing face of antibiotic prescribing: the mutant selection window |
| Q33573691 | The economic impact of once-daily versus conventional administration of gentamicin and tobramycin |
| Q46872366 | The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis |
| Q40517235 | The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents |
| Q40949894 | The place of tobramycin in lower respiratory tract infections (LRTI). |
| Q37409465 | Therapeutic drug monitoring of aminoglycosides in neonates |
| Q84145173 | Therapeutic drug monitoring of aminoglycosides in neonates |
| Q92481769 | Therapeutic drug monitoring of antibiotic agents: evaluation of predictive performance |
| Q70395083 | Three-year survey of amikacin use and aminoglycoside resistance in a general hospital in Belgium |
| Q34510556 | Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole |
| Q35653978 | Time course of trough serum gentamicin concentrations in preterm and term neonates |
| Q37940005 | Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis |
| Q34476089 | Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations |
| Q44910304 | Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration |
| Q42666715 | Tobramycin population pharmacokinetics in neonates. |
| Q71765938 | Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients |
| Q36607415 | Treatment of Pseudomonas aeruginosa infection in critically ill patients |
| Q39558431 | Treatment of gram-negative infections in patients with renal impairment: new alternatives to aminoglycosides |
| Q38035304 | Treatment of sepsis in an intensive care unit |
| Q38246118 | Treatment option for sepsis in children in the era of antibiotic resistance |
| Q39310965 | Treatment strategy for a multidrug-resistant Klebsiella UTI. |
| Q64071646 | Ultralow anterior resection with implantation of gentamicin-collagen sponge and no defunctioning stoma: anastomotic leakage and local cancer relapse |
| Q41435517 | Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations |
| Q33928671 | Use of antibacterial agents in renal failure |
| Q74550161 | Use of antibacterial agents in renal failure |
| Q36791058 | Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly |
| Q28379292 | Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy |
| Q35867409 | Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia |
| Q29012676 | Ventilator-associated pneumonia: diagnosis, treatment, and prevention |
| Q35176271 | Versatility of aminoglycosides and prospects for their future |
| Q34443407 | What do we really know about antibiotic pharmacodynamics? |
| Q79788312 | [Control scale of antibiotic prescriptions in intensive care] |
| Q78352702 | [Pharmacokinetic and pharmacodynamic concepts for an interpretative reading of the antibiogram] |
| Q80994130 | [Recommendations for antibiotic monitoring in ICU patients] |
| Q77197464 | [Selection of antibiotic-resistant bacteria: microbiological and pharmacological factors] |
Search more.